Involvement of NF‐κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats
Authors:
- 3 March 2022
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 36 (5) , e23016
Abstract
Prunetin (PRU) is an O‐methylated flavonoid that is present in various natural plants and a primary significant compound found in isoflavone. Liver cancer creates major carcinogenic death despite recently advanced therapies. Hepatocellular carcinoma (HCC) treatment and prognosis are better in people with secure liver function. In the present study, we evaluated the action of PRU on diethylnitrosamine (DEN) alone HCC in a rat model through inflammation‐mediated cell proliferative phosphoinositide 3‐kinase/protein kinase B (PI3K/AKT) pathway analysis. Male Wistar rats were divided into four groups of six rats each. Group I, normal rats; Group II, DEN alone; Group III, DEN + PRU, and Group IV, PRU‐alone. All groups of rats carried out hepatic cancer development by hypothesis antioxidant, biochemical, cell proliferative, apoptosis, cytokines protein, and gene expression status profiles. In tumor incidence DEN + PRU, 100% delayed the tumor growth disappearance of the lesion, and reversal of normal liver architecture was observed. Liver marker enzymes levels decreased when antioxidant levels (superoxidase dismutase, catalase, glutathione peroxidase, and glutathione reductase) were in Group III. Proinflammatory markers nuclear factor‐κB, interleukin (IL)‐6, IL‐1β, and tumor necrosis factor α, were elevated in the rat's serum in Group III. Cell proliferative markers proliferating cell nuclear antigen and Cyclin‐D1 protein expressions were downregulated; in contrast, Bcl‐2, Bax, caspase‐3, and caspase‐9 gene expressions were upregulated and then it followed that protein expression of PI3K/AKT was downregulated in PRU‐treated groups. PRU assisted reversal of liver damage, antioxidant enzyme restoration cytokine balance, protein, and gene expression to control levels. Taken together, PRU improves functions of the liver, and as such prevents HCC. PRU can be used together with chemopreventives for HCC.Keywords
This publication has 34 references indexed in Scilit:
- Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observationsTherapeutic Advances in Gastroenterology, 2013
- Alkaloids from Marine AscidiansMolecules, 2011
- The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic LeukemiasAdvances in Hematology, 2011
- Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and BidCell Death & Disease, 2010
- Role of free radicals in liver diseasesHepatology International, 2009
- Experimental mouse models for hepatocellular carcinoma researchInternational Journal of Experimental Pathology, 2009
- Ordering of caspases in cells undergoing apoptosis by the intrinsic pathwayCell Death & Differentiation, 2009
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Allosteric inhibition of human liver aldehyde dehydrogenase by the isoflavone prunetinBiochemical Pharmacology, 1997
- Selenium: Biochemical Role as a Component of Glutathione PeroxidaseScience, 1973